MX2020002501A - Formulaciones de nanoparticulas lipidas de vectores de adn libres de capsidos, no virales. - Google Patents

Formulaciones de nanoparticulas lipidas de vectores de adn libres de capsidos, no virales.

Info

Publication number
MX2020002501A
MX2020002501A MX2020002501A MX2020002501A MX2020002501A MX 2020002501 A MX2020002501 A MX 2020002501A MX 2020002501 A MX2020002501 A MX 2020002501A MX 2020002501 A MX2020002501 A MX 2020002501A MX 2020002501 A MX2020002501 A MX 2020002501A
Authority
MX
Mexico
Prior art keywords
capsid
viral
free dna
dna vectors
lipid nanoparticle
Prior art date
Application number
MX2020002501A
Other languages
English (en)
Inventor
Robert Michael Kotin
Ozan Alkan
Douglas Anthony Kerr
Ara Karl Malakian
Matthew John Simmons
Teresa L Wright
Matthew G Stanton
Jie Su
Original Assignee
Generation Bio Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Generation Bio Co filed Critical Generation Bio Co
Publication of MX2020002501A publication Critical patent/MX2020002501A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5176—Compounds of unknown constitution, e.g. material from plants or animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5123—Organic compounds, e.g. fats, sugars
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/14011—Baculoviridae
    • C12N2710/14111—Nucleopolyhedrovirus, e.g. autographa californica nucleopolyhedrovirus
    • C12N2710/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/14011—Baculoviridae
    • C12N2710/14111—Nucleopolyhedrovirus, e.g. autographa californica nucleopolyhedrovirus
    • C12N2710/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/14144—Chimeric viral vector comprising heterologous viral elements for production of another viral vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Virology (AREA)
  • Dispersion Chemistry (AREA)
  • Botany (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La presente invención se refiere a formulaciones de nanopartículas lípidas que comprenden un lípido ionizable y vectores de ADN libre de cápsido, no virales, con extremos covalentemente cerrados.
MX2020002501A 2017-09-08 2018-09-07 Formulaciones de nanoparticulas lipidas de vectores de adn libres de capsidos, no virales. MX2020002501A (es)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US201762556333P 2017-09-08 2017-09-08
US201762556334P 2017-09-08 2017-09-08
US201762556381P 2017-09-09 2017-09-09
US201862675327P 2018-05-23 2018-05-23
US201862675317P 2018-05-23 2018-05-23
US201862675324P 2018-05-23 2018-05-23
US201862675322P 2018-05-23 2018-05-23
PCT/US2018/050042 WO2019051289A1 (en) 2017-09-08 2018-09-07 FORMULATIONS OF LIPID NANOPARTICLES OF NON-VIRAL CAPSID-FREE DNA VECTORS

Publications (1)

Publication Number Publication Date
MX2020002501A true MX2020002501A (es) 2020-09-17

Family

ID=65635269

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020002501A MX2020002501A (es) 2017-09-08 2018-09-07 Formulaciones de nanoparticulas lipidas de vectores de adn libres de capsidos, no virales.

Country Status (15)

Country Link
US (1) US20210059953A1 (es)
EP (1) EP3679148A4 (es)
JP (2) JP2020537493A (es)
KR (1) KR20200051708A (es)
CN (1) CN111295448A (es)
AU (1) AU2018330208A1 (es)
BR (1) BR112020004219A2 (es)
CA (1) CA3075180A1 (es)
CO (1) CO2020002262A2 (es)
IL (1) IL272799A (es)
MA (1) MA50096A (es)
MX (1) MX2020002501A (es)
PH (1) PH12020500466A1 (es)
SG (1) SG11202000765PA (es)
WO (1) WO2019051289A1 (es)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA51842A (fr) * 2018-02-14 2020-12-23 Generation Bio Co Vecteurs d'adn non viraux et utilisations associées pour la production d'anticorps et de protéines de fusion
MA52709A (fr) * 2018-05-23 2021-03-31 Modernatx Inc Administration d'adn
JP2022542839A (ja) 2019-07-19 2022-10-07 フラッグシップ パイオニアリング イノベーションズ シックス，エルエルシー リコンビナーゼ組成物及び使用方法
EP4013879A4 (en) * 2019-08-12 2023-09-13 Generation Bio Co. METHODS AND COMPOSITIONS FOR REDUCING GENETIC OR NUCLEIC ACID THERAPY-RELATED IMMUNE RESPONSE
EP4025196A4 (en) * 2019-09-06 2023-07-12 Generation Bio Co. LIPID-NANOPARTICLE COMPOSITIONS WITH CLOSED-END DNA AND CLEAVABLE LIPIDS AND METHODS OF USE
US20220370357A1 (en) * 2019-11-22 2022-11-24 Generation Bio Co. Ionizable lipids and nanoparticle compositions thereof
CN110974954B (zh) * 2019-12-24 2021-03-16 珠海丽凡达生物技术有限公司 一种用于增强核酸疫苗免疫效果的脂质纳米颗粒及其制备方法
EP4153224A1 (en) 2020-05-20 2023-03-29 Flagship Pioneering Innovations VI, LLC Coronavirus antigen compositions and their uses
TW202208629A (zh) 2020-05-20 2022-03-01 美商旗艦先鋒創新有限責任公司 免疫原性組成物及其用途
EP4158032A2 (en) 2020-05-29 2023-04-05 Flagship Pioneering Innovations VI, LLC Trem compositions and methods relating thereto
CA3180101A1 (en) 2020-05-29 2021-12-02 Flagship Pioneering Innovations Vi, Llc Trem compositions and methods relating thereto
WO2022023284A1 (en) 2020-07-27 2022-02-03 Anjarium Biosciences Ag Compositions of dna molecules, methods of making therefor, and methods of use thereof
MX2023002439A (es) 2020-09-03 2023-05-09 Flagship Pioneering Innovations Vi Llc Composiciones immunogénicas y usos de las mismas.
GB202014751D0 (en) 2020-09-18 2020-11-04 Lightbio Ltd Targeting vector
KR20230124927A (ko) 2020-11-25 2023-08-28 아카제라 메디신즈, 인크. 핵산 전달을 위한 지질 나노입자, 및 관련 사용 방법
EP4267732A1 (en) 2020-12-23 2023-11-01 Flagship Pioneering Innovations VI, LLC Compositions of modified trems and uses thereof
WO2022155195A1 (en) * 2021-01-12 2022-07-21 Peranteau William Ionizable lipid nanoparticles for in utero mrna delivery
EP4313109A1 (en) 2021-03-31 2024-02-07 Flagship Pioneering Innovations V, Inc. Thanotransmission polypeptides and their use in treating cancer
EP4377457A1 (en) 2021-07-26 2024-06-05 Flagship Pioneering Innovations VI, LLC Trem compositions and uses thereof
EP4124348A1 (en) * 2021-07-30 2023-02-01 4basebio UK Ltd Nanoparticles for cell delivery
AR127073A1 (es) 2021-09-17 2023-12-13 Flagship Pioneering Innovations Vi Llc Composiciones y métodos para producir polirribonucleótidos circulares
TW202322826A (zh) 2021-10-18 2023-06-16 美商旗艦先鋒創新有限責任公司 用於純化多核糖核苷酸之組成物及方法
CA3238735A1 (en) 2021-11-24 2023-06-01 Jennifer A. Nelson Immunogenic compositions and their uses
AU2022397292A1 (en) 2021-11-24 2024-05-30 Flagship Pioneering Innovations Vi, Llc Varicella-zoster virus immunogen compositions and their uses
AU2022398478A1 (en) 2021-11-24 2024-06-13 Flagship Pioneering Innovations Vi, Llc Coronavirus immunogen compositions and their uses
TW202340460A (zh) 2021-12-17 2023-10-16 美商旗艦先鋒創新有限責任公司 用於在變性條件下富集環狀ｒｎａ之方法
TW202340461A (zh) 2021-12-22 2023-10-16 美商旗艦先鋒創新有限責任公司 用於純化多核糖核苷酸之組成物和方法
TW202342064A (zh) 2021-12-23 2023-11-01 美商旗艦先鋒創新有限責任公司 編碼抗融合多肽之環狀多核糖核苷酸
WO2023148303A1 (de) * 2022-02-02 2023-08-10 Mslsolutions Gmbh Verfahren zur medikament- und impfstoffherstellung
WO2023177655A1 (en) * 2022-03-14 2023-09-21 Generation Bio Co. Heterologous prime boost vaccine compositions and methods of use
WO2023183616A1 (en) 2022-03-25 2023-09-28 Senda Biosciences, Inc. Novel ionizable lipids and lipid nanoparticles and methods of using the same
TW202404614A (zh) * 2022-04-04 2024-02-01 美商星火治療公司 免疫增強及感染性疾病之治療
WO2023196634A2 (en) 2022-04-08 2023-10-12 Flagship Pioneering Innovations Vii, Llc Vaccines and related methods
WO2023220083A1 (en) 2022-05-09 2023-11-16 Flagship Pioneering Innovations Vi, Llc Trem compositions and methods of use for treating proliferative disorders
WO2023220729A2 (en) 2022-05-13 2023-11-16 Flagship Pioneering Innovations Vii, Llc Double stranded dna compositions and related methods
WO2023250112A1 (en) 2022-06-22 2023-12-28 Flagship Pioneering Innovations Vi, Llc Compositions of modified trems and uses thereof
US20240024505A1 (en) * 2022-07-12 2024-01-25 Trustees Of Boston University Synthetic cellular signaling pathways and uses thereof
US20240042021A1 (en) 2022-08-01 2024-02-08 Flagship Pioneering Innovations Vii, Llc Immunomodulatory proteins and related methods
KR102544632B1 (ko) * 2022-08-05 2023-06-16 주식회사 무진메디 장쇄 세라마이드가 포함된 지질 나노입자 및 이를 포함하는 세포 사멸용 조성물
WO2024035952A1 (en) 2022-08-12 2024-02-15 Remix Therapeutics Inc. Methods and compositions for modulating splicing at alternative splice sites
WO2024049979A2 (en) 2022-08-31 2024-03-07 Senda Biosciences, Inc. Novel ionizable lipids and lipid nanoparticles and methods of using the same
WO2024077191A1 (en) 2022-10-05 2024-04-11 Flagship Pioneering Innovations V, Inc. Nucleic acid molecules encoding trif and additionalpolypeptides and their use in treating cancer
WO2024097664A1 (en) 2022-10-31 2024-05-10 Flagship Pioneering Innovations Vi, Llc Compositions and methods for purifying polyribonucleotides
WO2024102799A1 (en) 2022-11-08 2024-05-16 Flagship Pioneering Innovations Vi, Llc Compositions and methods for producing circular polyribonucleotides

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5478745A (en) * 1992-12-04 1995-12-26 University Of Pittsburgh Recombinant viral vector system
US5869305A (en) * 1992-12-04 1999-02-09 The University Of Pittsburgh Recombinant viral vector system
DE10066104A1 (de) * 2000-09-08 2003-01-09 Medigene Ag Wirtszellen zur Verpackung von rekombinantem Adeno-assoziiertem Virus (rAAV), Verfahren zu ihrer Herstellung und deren Verwendung
SG158174A1 (en) * 2005-01-06 2010-01-29 Benitec Inc Rnai agents for maintenance of stem cells
HUE041875T2 (hu) * 2005-05-31 2019-06-28 Univ Colorado Regents Eljárás génbejuttatásra
EP1979485A2 (en) * 2006-01-31 2008-10-15 The Board Of Trustees Of The Leland Stanford Junior University Self-complementary parvoviral vectors, and methods for making and using the same
AU2016203992A1 (en) * 2009-05-11 2016-06-30 Berg Llc Methods for the diagnosis of metabolic disorders using epimetabolic shifters, multidimensional intracellular molecules, or environmental influencers
EP2500434A1 (en) * 2011-03-12 2012-09-19 Association Institut de Myologie Capsid-free AAV vectors, compositions, and methods for vector production and gene delivery
AU2013281328B2 (en) * 2012-06-27 2017-11-23 Meiragtx Uk Ii Limited Combination for treating an inflammatory disorder
AU2013355258A1 (en) * 2012-12-07 2015-06-11 Alnylam Pharmaceuticals, Inc. Improved nucleic acid lipid particle formulations
EP3446712A1 (en) * 2013-03-14 2019-02-27 Translate Bio Ma, Inc. Cftr mrna compositions and related methods and uses
SG11201510757PA (en) * 2013-05-21 2016-01-28 Univ Florida Capsid-modified, raav3 vector compositions and uses in gene therapy of human liver cancer
WO2015095346A1 (en) * 2013-12-19 2015-06-25 Novartis Ag Lipids and lipid compositions for the delivery of active agents
WO2016110518A1 (en) * 2015-01-07 2016-07-14 Universitat Autònoma De Barcelona Single-vector gene construct comprising insulin and glucokinase genes
WO2016172008A1 (en) * 2015-04-24 2016-10-27 University Of Massachusetts Modified aav constructions and uses thereof
AU2016377681B2 (en) * 2015-12-22 2021-05-13 Modernatx, Inc. Compounds and compositions for intracellular delivery of agents
DK3423110T3 (da) * 2016-03-03 2021-11-15 Univ Massachusetts Lineært duplex-dna med lukket ende til ikke-viral genoverførsel

Also Published As

Publication number Publication date
CN111295448A (zh) 2020-06-16
AU2018330208A1 (en) 2020-02-27
IL272799A (en) 2020-04-30
WO2019051289A9 (en) 2019-06-20
CO2020002262A2 (es) 2020-05-29
MA50096A (fr) 2020-07-15
JP2020537493A (ja) 2020-12-24
KR20200051708A (ko) 2020-05-13
BR112020004219A2 (pt) 2020-09-08
PH12020500466A1 (en) 2021-01-25
WO2019051289A1 (en) 2019-03-14
CA3075180A1 (en) 2019-03-14
EP3679148A1 (en) 2020-07-15
RU2020110805A3 (es) 2022-01-19
JP2023002828A (ja) 2023-01-10
SG11202000765PA (en) 2020-03-30
EP3679148A4 (en) 2021-06-09
US20210059953A1 (en) 2021-03-04
RU2020110805A (ru) 2021-10-11

Similar Documents

Publication Publication Date Title
PH12020500466A1 (en) Lipid nanoparticle formulations of non-viral, capsid-free dna vectors
IL268888A (en) Multispecific binding proteins targeting CAIX, ANOI, mesothelin, TROP2, CEA, or CLAUDIN-18.2
MY194032A (en) Anti-tigit antibodies, anti-pvrig antibodies and combinations thereof
MX2020007148A (es) Formulaciones.
PH12018502645A1 (en) Optimized mini-dystrophin genes and expression cassettes and their use
SG11202003754YA (en) High concentration protein formulations with reduced viscosity
CY1120373T1 (el) Συνθεσεις που περιλαμβανουν βακτηριακα στελεχη
MX2020003596A (es) Composiciones de acido nucleico-polipeptido y usos de las mismos.
MX2023004479A (es) Sistema de vector multiple y sus usos.
MX2018009750A (es) Composiciones potenciadoras de vcn y métodos para su uso.
EP4219532A3 (en) Compositions and methods for transient gene therapy with enhanced stability
PH12018500568A1 (en) Antisense nucleic acid
MX2018002106A (es) Vacunas terapeuticas contra el hpv18.
MX2017016400A (es) Vectores para uso en un sistema de coexpresion inducible.
MA40902A (fr) Vaccins hpv16 thérapeutiques
EP3595629A4 (en) NONVIRAL, NONCATIONIC NANOPARTICLE AND USES THEREOF
EP3615079A4 (en) STABLE CANNABINOID FORMULATIONS
SA519401756B1 (ar) أجزاء منشأة للتعبير الوراثي عن رنح فريدريك
BR112018070497A2 (pt) métodos e formulações farmacêuticas para tratamento de condições oculares
IL268515A (en) Evolocumab formulations with high concentration and low viscosity and methods for their preparation
MX2021006674A (es) Composiciones para estabilizar bacterias y usos de las mismas.
IL287435A (en) Stable, low-viscosity antibody formulations and their uses
WO2018183692A8 (en) VECTORS AND COMPOSITIONS FOR THE TREATMENT OF HEMOGLOBINOPATHIES
MY185720A (en) Ink based on nanoparticles of silver
EP3595693A4 (en) CANNABINOID FORMULATIONS AND DOSAGE